Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: bone morphogenetic protein activators - Curis

Drug Profile

Research programme: bone morphogenetic protein activators - Curis

Alternative Names: BMP activators; BMP agonists; BMP-7 protein; eptotermin alfa analogues; eptotermin alfa mimetics

Latest Information Update: 19 Jan 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Curis
  • Class Small molecules
  • Mechanism of Action Bone morphogenetic protein activators; Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Kidney disorders; Neurological disorders; Vascular disorders

Most Recent Events

  • 22 May 2007 This research programme is available for licensing worldwide (http://www.curis.com)
  • 19 May 2007 Ortho Biotech Products terminates its worldwide licence to this research programme
  • 12 Dec 2005 Curis and Centocor expanded their collaboration agreement to screen and validate small molecule agonists based on Curis' BMP technology portfolio
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top